GAL and cancer: 300 μM CPI in combination with 30 μM galloflavin (median: 0.29, IQR: 0.17–0.40 absorbance at 450 nm) induced a significant reduction of cancer cell proliferation compared to the DMSO control (median: 1.00, IQR: 0.78–1.15) and to both monotherapies (CPI: median: 0.60, IQR: 0.53–0.67; Gal: median: 0.66, IQR: 0.44–0.93, Fig 2B).